Table 1.
Probability calculations of vaso-occlusive crisis (VOC) episodes, health utilities before and after VOC occurrences, and disutilities associated with VOCs and adverse effects
| Probability of VOC occurrence in therapeutic settings | VOC+ | VOC- |
|---|---|---|
| Low-dose crizanlizumab | 0.33 | 0.67 |
| Low-dose crizanlizumab+hydroxyurea | +0.18 | 0.82 |
| High- dose crizanlizumab | 0.17 | 0.83 |
| High-dose crizanlizumab+hydroxyurea | 0.25 | 0.75 |
| Hydroxyurea | 0.4 | 0.6 |
| No treatment (placebo) | 0.33 | 0.67 |
| Base utility in SCD patients | 0.75 18 | |
| VOC-associated disutility in SCD patients | -0.1 19 | |
| Disutility of adverse effects 20 | ||
| Headache | -0.069 | |
| Back pain | -0.069 | |
| Nausea | -0.048 | |
| Arthralgia | -0.069 | |
| Pain in the extremities | -0.069 | |
| Pyrexia | -0.110 | |
| Musculoskeletal pain | -0.069 | |
| Vomiting | -0.048 | |
VOC+: Vaso-occlusive crisis occurrence; VOC-: Lack of vaso-occlusive crisis; SCD: Sickle cell disease